Status:
COMPLETED
Tubular Markers in Response to Saxagliptin Therapy
Lead Sponsor:
Beni-Suef University
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18-80 years
Phase:
PHASE4
Brief Summary
the study aims to investigate whether treatment with saxagliptin would induce beneficial changes in renal NGAL and L-FABP biomarkers and if they would be used as a tool to identify patients' categorie...
Detailed Description
Diabetic kidney disease (DKD) is considered a substantial cause of end-stage kidney disease (ESKD) worldwide. Incorporation of renoprotective options during interventions to prevent the development of...
Eligibility Criteria
Inclusion
- T2 DM,
- prevalent albuminuria (30-3000mg/g),
- controlled hypertension (defined as blood pressure \<140/90 mm Hg) on a selected angiotensin receptor blocker, olmesartan 20mg/day for at least 4 weeks before intervention.
Exclusion
- type 1 diabetes,
- poorly controlled hypertension (140-160/90-100 mm Hg),
- pancreatitis,
- malignancies
- albuminuria more than 3000mg/g.
- cardiovascular diseases (acute myocardial infarction, cerebrovascular disease in the past 6months,
- End Stage Renal Disease (ESRD) on chronic dialysis, renal transplant, a serum creatinine \>6.0 mg/dL, or estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2.
Key Trial Info
Start Date :
March 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2020
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT04521049
Start Date
March 1 2019
End Date
April 1 2020
Last Update
August 20 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of Pharmacy
Al Qāhirah al Jadīdah, Egypt, 0004